Recent studies on the small molecule inhibitor DC‐Y13‐27, targeting YTHDF2, indicate it can enhance tumour response to radiotherapy and immunotherapy, providing a novel therapeutic strategy for cancer treatment.188. Here, YTHDF2 is linked to neoplasm.